Superparamagnetic iron oxide nanoparticles for MRI: Contrast media pharmaceutical company R&D perspective

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 5, 2013, Pages 411-422

  Corot, Claire ^a   Warlin, David ^a  

^a Laboratoire Guerbet   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL APPLICATION; CLINICAL DEVELOPMENT; ECONOMIC CHALLENGES; PHARMACEUTICAL COMPANY; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES; TECHNOLOGICAL DEVELOPMENT; THERAPEUTIC DRUGS; THERAPEUTIC TREATMENTS;

CONTRAST MEDIA; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; STEM CELLS; SUPERPARAMAGNETISM;

NANOPARTICLES;

FERUCARBOTRAN; GADOLINIUM CHELATE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; CANCER PATIENT; CELL MIGRATION; CELL TRACKING; DRUG HALF LIFE; DRUG INDUSTRY; DRUG SAFETY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMMUNOCOMPETENT CELL; KUPFFER CELL; MACROPHAGE; MEDICAL CARE; MEDICAL PRACTICE; MOLECULAR IMAGING; MOLECULAR MEDICINE; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PELVIS CANCER; PERSONALIZED MEDICINE; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; SENSITIVITY AND SPECIFICITY; STEM CELL;

ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; DRUG INDUSTRY; FERRIC COMPOUNDS; HUMANS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; METAL NANOPARTICLES; NANOTECHNOLOGY; PHAGOCYTOSIS; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84884818329     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1225     Document Type: Article

References (59)

1. Corot C, Robert P, Idée JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504.
2. Laurent S, Forge D, Port M, Roch A, Robic C, Vander Elst L, Muller RN. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem Rev 2008, 108:2064-2110. Erratum in: Chem Rev 2010, 110:2574.
3. Corot C, Port M, Guilbert I, Robert P, Raynal I, Robic C, Raynaud JS, Prigent P, Dencausse A, Idée JM. Chapter 4: Superparamagnetic contrast agents. In: Modo M, Bulte J, eds. Molecular and Cellular MR Imaging. Boca Raton, FL: CRC Press; 2007, 59-83.
4. Wang Y-XJ. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg 2011, 1:35-40.
5. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3:137-140.
6. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006, 41:206-212.
7. Agdeppa ED, Spilker ME. A review of imaging agent development. Am Assoc Pharm Scient J 2009, 11:286-299.
8. Corot C, Idée JM, Raynaud JS, Salazar JF, Catoen S. In vivo imaging for biodistribution and metabolism evaluations of new chemical entities. Ann Pharm Fr 2012, 70:26-34.
9. Heesakkers RAM, Jager GJ, Hovels AM, De Hoop B, Ven Den Bosch HCM, Raat F, Witjez JA, Mulders PFA, Van Der Kaa CH, Barentsz JO. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR Imaging. Radiology 2009, 251:408-414.
10. Saokar A, Gee MS, Islam T, Mueller PR, Harisinghani MG. Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10. Clin Imaging 2010, 34:448-452.
11. Triantafyllou M, Studer EU, Birkhauser FD, Fleischman A, Bains LJ, Petralia G, Christe A, Froehlich JM, Thoeny HC. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer 2012, 49:616-624.
12. Available at: http://www.emea.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000801/wapp/Initial_authorisation/human_wapp_000064.jsp
13. Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, U-King-Im JM, Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of macrophage Activity) study: evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid diseases. J Am Coll Cardiol 2009, 53:2039-2050.
14. Degnan AJ, Patterson AJ, Tang TY, Howarth SPS, Gillard JH. Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: follow-up of the ATHEROMA trial. Cerebrovasc Dis 2012, 34:169-173.
15. Dousset V, Brochet B, Deloire MSA, Lagoarde L, Barroso B, Caille JM, Petry KG. MR Imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolium. Am J Neuroradiol 2006, 27:1000-1005.
16. Tourdias T, Roggerone S, Filippi M, Kanagaki M, Rovaris M, Miller DH, Petry KG, Brochet B, Pruvo JP, Radue EW, et al. Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR Imaging. Radiology 2012, 264:225-233.
17. Lefevre S, Ruimy D, Jehl F, Neuville A, Robert P, Sordet C, Ehlinger M, Dietemann JL, Bierry G. Septic arthritis: monitoring with USPIO-enhanced macrophage MR imaging. Radiology 2011, 258:722-728.
18. Richards JM, Semple SI, MacGillivray TJ, Gray C, Langrish JP, Williams M, Dweck M, Wallace W, McKillop G, Chalmers RT, et al. Abdominal aortic aneurysm growth predicted by uptake of ultrasmall superparamagnetic particles of iron oxide: a pilot study. Circ Cardiovasc Imaging 2011, 4:274-281.
19. Chauveau F, Cho TH, Berthezene Y, Nighoghossian N, Wiart M. Imaging inflammation in stroke using magnetic resonance imaging. Int J Clin Pharmacol Ther 2010, 11:718-728.
20. Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, et al. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin Cancer Res 2011, 17:5695-5704.
21. Corot C, Petry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, Blezer E, Rausch M, Brochet B, Foster-Gareau P, et al. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol 2004, 39:619-625.
22. Canet-Soulas E, Letourneur D. Biomarkers of atherosclerosis and the potential of MRI for the diagnosis of vulnerable plaque. MAGMA 2007, 20:129-142.
23. Srihasan K, Sullivan K, Savage T, Livingstone M. Noninvasive functional MRI in alert monkeys. Neuroimage 2010, 51:267-273.
24. Troprès I, Lamalle L, Farion R, Segebarth C, Rémy C. Vessel size imaging using low intravascular contrast agent concentrations. MAGMA 2004, 17:313-316.
25. McCullough BJ, Kolokythas O, Maki JH, Green DE. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 2012. doi: 10.1002/jmri.23879.
26. FDA. Guidance for industry developing medical imaging drug and biological products. Part 3: design, analysis, and interpretation of clinical studies, 2004. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ucm071604.pdf (Accessed August 25, 2005).
27. EMA. Guideline on clinical evaluation of diagnostic agents. London, 2009. Available at: http://qibawiki.rsna.org/images/1/1a/EU.2009.08.04_Guideline_on_Clinical_evaluation_of_diagnostic_agents.pdf. (Accessed June 26, 2008).
28. FDA. Guidance for industry standards for clinical trial imaging endpoints draft guidance, 2011. Available at: http://interactive.snm.org/docs/Draft%20Guidance%20for%20Clincal%20Trial%20Imaging%20Endpoints1.pdf. (Accessed August 8, 2011).
29. EMEA. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000745/WC500047537.pdf p. 23. (Accessed June 9, 2007).
30. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021711s000_MedR_P1.pdf (Accessed December 12, 2008).
31. Available at: http://www.medscape.com/viewarticle/736117 (Accessed January 20, 2011).
32. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm299678.htm (Accessed April 10, 2012).
33. Available at: http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4390m1-final.pdf (Accessed December 10, 2008).
34. ® (Perflubutane polymer microspheres) injectable suspension for the assessment of the coronary artery disease. Expert Rev Cardiovasc Ther 2007, 5:413-421.
35. Dorfman GS, Sullivan DC, Schnall MD, Matrisian LM. The translational research working group developmental pathway for image-based assessment modalities. Clin Cancer Res 2008, 14:5678-5684.
36. Baker LC, Atlas WC, Afendulis CC. Expanded use of imaging technology and the challenge of measuring value. Health Aff 2008, 27:1467-1478.
37. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010, 9:363-366.
38. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012, 72:4875-4882.
39. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010, 7:1899-1912.
40. Sullivan DC. Imaging as a quantitative science. Radiology 2008, 248:328-332.
41. O'Connor JPB, Jackson A, Asselin MC, Buckley D, Parker GM, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol 2008, 9:766-776.
42. Corot C, Robert P, Ballet S, Gonzalez W, Idée JM, Raynal I, Port M. Chapter 21: T1-weighted MR contrast agents for cancer research. In: Chen X, ed. Molecular Imaging Probes for Cancer Research. Singapore: World Scientific Publishing Co Pte Ltd; 2012, 611-658.
43. Baio G, Neumaier CE. Chapter 22: T2 weighted MR contrast agents for cancer research. In: Chen X, ed. Molecular Imaging Probes for Cancer Research. Singapore: World Scientific Publishing Co Pte Ltd; 2012, 659-688.
44. Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Vander Elst L, Muller RN. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol 2012, 32:e36-e48.
45. Yang J, Wadghiri YZ, Hoang DM, Tsui W, Sun Y, Chung E, Li Y, Wang A, De Leon M, Wisniewski T. Detection of amyloid plaques targeted by USPIO-Ab1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 2011, 55:1600-1609.
46. Meier R, Henning TD, Boddington S, Tavri S, Arora S, Piontek G, Rudelius M, Corot C, Daldrup-Link HE. Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology 2010, 255:527-535.
47. Zimmermann RG. Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals. Nucl Med Biol 2013, 40:155-166.
48. Janowski M, Bulte JW, Walczak P. Personalized nanomedicine advancements for stem cell tracking. Adv Drug Deliv Rev 2012, 64:1488-1507.
49. Srinivas M, Aarntzen EH, Bulte JW. Imaging of cellular therapies. Adv Drug Deliv Rev 2010, 62:1080-1093.
50. Ottobrini L, Martelli C, Lucignani G. Chapter 30: Imaging cell trafficking in cancer research. In: Chen X, ed. Molecular Imaging Probes for Cancer Research. Singapore: World Scientific Publishing Co Pte Ltd; 2012, 905-948.
51. Miller I, Ashton-Chess J, Spolders H, Fert V, Ferrara J, Kroll W, Askaa J, Larcier P, Terry PF, Bruinvels A, et al. Market access challenges in the EU for high medical value diagnostic tests. Pers Med 2011, 8:137-148.
52. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, Konig F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov 2010, 9:277-291.
53. Woosley RL. Is it possible for FDA regulatory scientists and industry scientists to work together? Clin Pharmacol Ther 2012, 91:390-392.
54. Goodman JL. Transforming regulatory science 2012: making a difference. Clin Pharmacol Ther 2012, 91:375-377.
55. Opar A. Bridging the drug-diagnostic divide. Nat Rev Drug Discov 2011, 10:323-324.
56. Eck SL, Paul SM. Biomarker qualification via public-private partnership. Clin Pharmacol Ther 2010, 87:21-23.
57. Wagner JA. Open-minded to open innovation and precompetitive collaboration. Clin Pharmacol Ther 2010, 87:511-515.
58. ADNI Alzheimer Disease National Initiative Available at: http://www.adni-info.org/ 2013
59. SNM Society of Nuclear Medicine Newsletters Available at: http://interactive.snm.org/docs/MI_Gateway_Newsletter_2012-4.pdf.